RAMOS(RA1) 人B淋巴细胞瘤产品图

RAMOS(RA1) 人B淋巴细胞瘤

收藏
  • 询价
  • ATCC中国传代
  • 美国
  • RAMOS(RA1)
  • 2026年07月12日
    avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 供应商

      ATCC

    • 品系

      查询相关资料

    • 组织来源

      人B淋巴细胞瘤

    • 相关疾病

      查询相关资料

    • 物种来源

    • 免疫类型

      查询相关资料

    • 是否是肿瘤细胞

    • 器官来源

    • 运输方式

      常温

    • 生长状态

      正常

    • 库存

      大量

    CRL-1596 RAMOS(RA 1) 人B淋巴细胞瘤,原代细胞|细胞系|细胞株|菌种;细胞库管理规范,提供的细胞株背景清楚,提供参考文献和最优培养条件!

    CRL-1596 RAMOS(RA 1) 人B淋巴细胞瘤 的详细介绍
    CRL-1596 RAMOS(RA 1) 人B淋巴细胞
    ATCC® Number: CRL-1596™ Price: $256.00
    Designations: Ramos (RA 1)
    Depositors: BC Giovanella
    Isotype: IgM; lambda light chain
    Biosafety Level: 1
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: suspension
    Organism: Homo sapiens (human)
    Morphology: lymphoblast
    Source: Disease: Burkitt's lymphoma (American)
    Cell Type: B lymphocyte;
    Cellular Products: immunoglobulin (surface and secreted) [1093] [22747]
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
    Applications: transfection host (Nucleofection technology from Lonza)
    Receptors: interleukin 4 (IL-4); low affinity IgE (CD23) [23468]
    Tumorigenic: Yes
    Antigen Expression: CD23 + [23468]
    DNA Profile (STR): Amelogenin: X
    CSF1PO: 10,11
    D13S317: 13,14
    D16S539: 10,13
    D5S818: 7,12
    D7S820: 11
    THO1: 7,9.3
    TPOX: 8,9
    vWA: 15,16
    Age: 3 years
    Gender: male
    Ethnicity: Caucasian
    Comments: The cells are negative for Epstein-Barr virus. [22747]
    Both the parental line (ATCC CRL-1596)and the derivative cell line Ramos.2G6.4C10 (ATCC CRL-1923) have about 1500 IL-4 binding sites per cell. [23389]
    The cells are reported to secrete IgM (lambda light chain). [1093]
    Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: heat-inactivated fetal bovine serum to a final concentration of 10%.
    Temperature: 37.0°C
    Subculturing: Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
    Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml.
    Maintain cell density between 2 X 10 exp5 and 1 X 10 exp6 viable cells/ml.
    Preservation: culture medium 95%; DMSO, 5%
    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
    derivative:ATCC CRL-1923
    References: 1093: Benjamin D, et al. Immunoglobulin secretion by cell lines derived from African and American undifferentiated lymphomas of Burkitt's and non-Burkitt's type. J. Immunol. 129: 1336-1342, 1982. PubMed: 6286763
    22747: Klein G, et al. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology 5: 319-334, 1975. PubMed: 181343
    23389: Siegel JP, Mostowski HS. A bioassay for the measurement of human interleukin-4. J. Immunol. Methods 132: 287-295, 1990. PubMed: 1698879
    23468: Rousset F, et al. Regulation of Fc receptor for IgE (CD23) and class II MHC antigen expression on Burkitt's lymphoma cell lines by human IL-4 and IFN-gamma. J. Immunol. 140: 2625-2632, 1988. PubMed: 2965726
    26047: Nilsson K, et al. Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int. J. Cancer 19: 337-344, 1977. PubMed: 14896
    32796: Bloom TJ, Beavo JA. Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. Proc. Natl. Acad. Sci. USA 93: 14188-14192, 1996. PubMed: 8943082

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • 人类组织肿细胞

      人前列腺癌细胞 RAJI  黑人Burkitt淋巴 RAMOS  人B淋巴细胞瘤 RAMOS(RA.1)  人B淋巴细胞瘤 RPMI-8226  人多发骨髓细胞 SaOS-2  人骨肉细胞 SF126  人脑 SF17  人脑 SF17  人脑 SF763  人脑 SF767  人脑 SH-SY5Y  人骨髓神经母细胞 SK-BR-3  人乳腺癌细胞 SK-HEL-1  人皮肤黑色素细胞 SK-N-SH  人神经母细胞 SK-OV-3  人卵巢

    • CAR-T细胞的特异性杀伤及耗竭表征

      细胞表面标志物和指示T细胞活化和肿细胞杀伤的分泌蛋白进行量化。结果显示,当与抗原阳性的Ramos细胞结合时,CD8+细胞上的T细胞活化标志物CD69、CD25和PD-1(分别为图2A-C)迅速上调。该上调表现出一定的时间依赖性,在第7天观察到的水平最高,但CAR-T细胞密度之间几乎没有差异。在与抗原阴性的Jurkat细胞共培养或在有模拟转导的T细胞存在的情况下,所有3种活化标志物的表达均很低(   图2. 抗-CD19 CAR-T的抗原特异性活化 应用案例2 抗原激发下CAR-T细胞的耗竭表征 重复

    • 31600篇!CUSABIO 7月文献引用再破记录,200篇新文献为科研助力

      基因,揭示同一基因在不同细胞类型中可呈相反预后效应。结合Xenium空间转录组分析预后分层细胞类型的空间分布与治疗响应关系,并验证PLOD2为跨八种细胞类型的泛预后不良靶点,开发的PROTAC-G3降解剂在体内有效抑制肿进展。CUSABIO产品用于提供重组PLOD2蛋白用于SPR结合亲和力测定。 02 标题:Gut pathobionts translocate into liver and reshape intrahepatic microbiome

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1.10
    蒂科(上海)生物科技有限公司
    2025年05月20日询价
    询价
    上海彩佑实业有限公司
    2025年05月10日询价
    ¥1800
    上海晶风生物科技有限公司
    2025年06月03日询价
    询价
    上海雅吉生物科技有限公司
    2025年06月30日询价
    询价
    齐一生物科技(上海)有限公司
    2025年10月30日询价
    RAMOS(RA1) 人B淋巴细胞瘤
    询价